Cargando…

Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment

PURPOSE: Cardiovascular disease (CVD) risk assessment is an important strategy for the prevention of CVD. Pharmacists play an important role in CVD risk assessment and management (CVDRAM). Our previous study identified gaps in knowledge among community pharmacists for the provision of CVDRAM service...

Descripción completa

Detalles Bibliográficos
Autores principales: Zolezzi, Monica, Abdallah, Oraib, Sankaralingam, Sowndramalingam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319523/
https://www.ncbi.nlm.nih.gov/pubmed/32607030
http://dx.doi.org/10.2147/RMHP.S231075
_version_ 1783551069532454912
author Zolezzi, Monica
Abdallah, Oraib
Sankaralingam, Sowndramalingam
author_facet Zolezzi, Monica
Abdallah, Oraib
Sankaralingam, Sowndramalingam
author_sort Zolezzi, Monica
collection PubMed
description PURPOSE: Cardiovascular disease (CVD) risk assessment is an important strategy for the prevention of CVD. Pharmacists play an important role in CVD risk assessment and management (CVDRAM). Our previous study identified gaps in knowledge among community pharmacists for the provision of CVDRAM services as assessed through patient simulation. Therefore, our objectives were: a) to develop and evaluate an educational program on CVD risk assessment for community pharmacists, b) to assess the knowledge and skills of participating pharmacists in assessing and managing CVD risk before and after enrolling in the educational program and c) to explore pharmacists’ satisfaction and perceived effectiveness of the educational program. METHODS: Using a blended learning instructional approach, the educational program for a subset of 25 community pharmacists recruited from our previous study consisted of two face-to-face workshops, and an online 5-module course on CVD risk factors such as hyperlipidemia, hypertension, diabetes, obesity, and smoking cessation based on principles of adult learning. A repeated measures study design was utilized by measuring participants’ knowledge on pre- and post-questionnaires and an objective structured clinical examination (OSCE) at the conclusion of the educational program was also used to assess its impact on the knowledge and skills of community pharmacists in the provision of CVD risk assessment and management (CVDRAM) services. The knowledge questionnaire was completed by 23 pharmacists while the OSCE was completed by 8 pharmacists. In addition, a survey assessed the pharmacists’ level of satisfaction with the educational program. RESULTS: At the conclusion of the educational program, the participating pharmacists achieved knowledge and skills for the provision of CVDRAM services. Knowledge scores in relation to CVDRAM significantly improved after the educational program [out of a maximum of 20 points, the median (interquartile range) = 9 (7–9) at pre- vs 12 (12–13) at post-educational program], p<0.001. On the OSCE, the median (interquartile range) scores for Stations 1 and 2 were 66 (63–71) and 71 (67–76), respectively. Out of the 21 pharmacists that completed the satisfaction survey, 71% were very satisfied and 29% were satisfied with the educational program. CONCLUSION: The educational program improved pharmacists’ knowledge and skills for the provision of CVDRAM services.
format Online
Article
Text
id pubmed-7319523
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73195232020-06-29 Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment Zolezzi, Monica Abdallah, Oraib Sankaralingam, Sowndramalingam Risk Manag Healthc Policy Original Research PURPOSE: Cardiovascular disease (CVD) risk assessment is an important strategy for the prevention of CVD. Pharmacists play an important role in CVD risk assessment and management (CVDRAM). Our previous study identified gaps in knowledge among community pharmacists for the provision of CVDRAM services as assessed through patient simulation. Therefore, our objectives were: a) to develop and evaluate an educational program on CVD risk assessment for community pharmacists, b) to assess the knowledge and skills of participating pharmacists in assessing and managing CVD risk before and after enrolling in the educational program and c) to explore pharmacists’ satisfaction and perceived effectiveness of the educational program. METHODS: Using a blended learning instructional approach, the educational program for a subset of 25 community pharmacists recruited from our previous study consisted of two face-to-face workshops, and an online 5-module course on CVD risk factors such as hyperlipidemia, hypertension, diabetes, obesity, and smoking cessation based on principles of adult learning. A repeated measures study design was utilized by measuring participants’ knowledge on pre- and post-questionnaires and an objective structured clinical examination (OSCE) at the conclusion of the educational program was also used to assess its impact on the knowledge and skills of community pharmacists in the provision of CVD risk assessment and management (CVDRAM) services. The knowledge questionnaire was completed by 23 pharmacists while the OSCE was completed by 8 pharmacists. In addition, a survey assessed the pharmacists’ level of satisfaction with the educational program. RESULTS: At the conclusion of the educational program, the participating pharmacists achieved knowledge and skills for the provision of CVDRAM services. Knowledge scores in relation to CVDRAM significantly improved after the educational program [out of a maximum of 20 points, the median (interquartile range) = 9 (7–9) at pre- vs 12 (12–13) at post-educational program], p<0.001. On the OSCE, the median (interquartile range) scores for Stations 1 and 2 were 66 (63–71) and 71 (67–76), respectively. Out of the 21 pharmacists that completed the satisfaction survey, 71% were very satisfied and 29% were satisfied with the educational program. CONCLUSION: The educational program improved pharmacists’ knowledge and skills for the provision of CVDRAM services. Dove 2020-06-22 /pmc/articles/PMC7319523/ /pubmed/32607030 http://dx.doi.org/10.2147/RMHP.S231075 Text en © 2020 Zolezzi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zolezzi, Monica
Abdallah, Oraib
Sankaralingam, Sowndramalingam
Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment
title Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment
title_full Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment
title_fullStr Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment
title_full_unstemmed Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment
title_short Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment
title_sort development and evaluation of an educational program for community pharmacists on cardiovascular risk assessment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319523/
https://www.ncbi.nlm.nih.gov/pubmed/32607030
http://dx.doi.org/10.2147/RMHP.S231075
work_keys_str_mv AT zolezzimonica developmentandevaluationofaneducationalprogramforcommunitypharmacistsoncardiovascularriskassessment
AT abdallahoraib developmentandevaluationofaneducationalprogramforcommunitypharmacistsoncardiovascularriskassessment
AT sankaralingamsowndramalingam developmentandevaluationofaneducationalprogramforcommunitypharmacistsoncardiovascularriskassessment